Abstract:Rationale: Silodosin (SDN) is a novel α1 -adrenoceptor antagonist in the treatment of benign prostatic hyperplasia (BPH). The presence of degradation products in a drug affects not only the quality, but also the safety and efficacy of drug formulation. Thus, it is essential to develop an efficient analytical method which could be useful to selectively separate, identify and characterise of all possible degradation products of SDN which is mandatory in drug development processes. Methods: SDN was subjected to forced degradation under hydrolytic (acid, base and neutral), oxidative, photolytic and thermal stress conditions. Separation of the drug and degradation products was achieved by a liquid chromatography (LC) method using an Acquity UPLC® BEH C18 (2.1 × 100 mm, 1.7 μm; Waters) column with mobile phase consisting of 0.1% formic acid (FA) in water (A) and 0.1% FA in acetonitrile (ACN) and methanol (MeOH) (1:1) (B) as organic modifier at a flow rate of 0.15 mL min-1 in gradient elution mode. Identification and characterization of the degradation products was performed by mass spectrometry methods using an LTQ-Orbitrap mass spectrometer. Results: A total of five degradation products (DP1 to DP5) were formed under various stress conditions and their structures were proposed with the help of tandem mass spectrometry (MS/MS) experiments and high-resolution mass spectral data. A common degradation product (DP1) was observed under acidic and basic degradation conditions. DP2 was observed under acidic, DP4 and DP5 were observed under basic hydrolytic conditions, whereas DP3 was observed under oxidative conditions. Conclusions: SDN was found to be labile under hydrolytic and oxidative conditions. The structures of all the degradation products were proposed. The most rational mechanisms for the formation of the degradation products under different stress conditions have been established. The proposed method can be effectively used to carry out the determination and detection of SDN and its degradation products. Copyright © 2017 John Wiley & Sons, Ltd.

An unexpected degradation pathway of N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231), a pH sensitive prodrug of HNO, in a prototype formulation solution

Degradation of Ciprofloxacin Using Α-Mno2 Activated Peroxymonosulfate Process: Effect of Water Constituents, Degradation Intermediates and Toxicity Evaluation

Degradation kinetics and mechanism of an oxadiazole derivative, design of a stable drug product for BMS-708163, a γ-secretase inhibitor drug candidate.

Identification and characterization of two new oxidation degradation impurities in cinnarizine through LC‐HRMS/MS and 1H NMR, along with in silico toxicity predictions of its degradation products

Study of degradation mechanisms of cyclobenzaprine by LC-MS/MS

Investigation of an artificial solution degradant of linagliptin: An undesired linagliptin urea derivative generates in sample preparation of linagliptin tablet treated by sonication in acetonitrile containing diluent

Oxidative stress-induced degradation of Brinzolamide: Isolation and in-depth characterization of unique hydroxylamine and oxime degradation products

Unveiling Pretomanid profiling using LC–MS/MS: integrating in-silico toxicity assessment and molecular docking analysis

A critical assessment on stability behaviour of Vorinostat using LC-MS-QTOF with H/D exchange and NMR

Forced Degradation Study of an Anti‐Diabetic Drug Imeglimin: Impurity Profiling and Structure Elucidation Using LC‐Q‐ToF‐MS/MS and NMR

Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry

A novel stability indicating mass compatible reversed‐phase high‐performance liquid chromatography for the determination of Diroximel fumarate and its related impurities

Forced Degradation Studies of Elagolix Sodium with the Implementation of High Resolution LC-UV-PDA-MSn (N=1,2, 3…) and NMR Structural Elucidation

Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.

Forced degradation studies of elagolix sodium with the implementation of high resolution LC-UV-PDA-MS n (n=1,2,3...) and NMR structural elucidation

Structure Elucidation and Mechanistic Study of a New Dimeric Degradant in Ropinirole Hydrochloride Extended-Release Tablets

Diclofenac Sodium Stability in Simulated Gastrointestinal Fluids and the Use of MCM-41 Silica Carrier with Surface Modification to Achieve Innovative Delayed Release

Degradation of a pharmaceutical in HPLC grade methanol containing trace level formaldehyde

Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC-MS/MS.

Mechanistic Studies on A P450-Mediated Rearrangement of Bms-690514: Conversion of A Pyrrolotriazine to A Hydroxypyridotriazine

Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals.